DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for exfoliation syndrome — screening already-approved drugs against its 18-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleExfoliation syndrome maps to a 18-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for exfoliation syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
GDP-mannose 4,6-dehydratase (GMDS) — GMDS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet napdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6GPK · 1.47 Å · ligand NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NAP). Experimental structure, not a prediction.
What the evidence adds up to
Across three Finnish surveys covering 795 people, the mean prevalence of exfoliation syndrome was 22.4%. Prevalence rose with age: 14.2% in those aged 60–69, 21.9% in those aged 70–79, and 34.7% in those aged 80 or older. No isolated clustering was found, and the figures were considered representative of the whole country.
A 2006 study examined 17 sons and daughters (mean age 50.3 years) of patients with exfoliation syndrome. None had clinically evident disease, but conjunctival biopsies examined by transmission electron microscopy found precursor material in five of the 17 specimens. The authors concluded that early deposition of exfoliation material can be found in middle-aged offspring, substantiating a hereditary predisposition.
The condition is age-related and systemic, with the best-known link being to glaucoma. All parts of the eye may be affected, but the connection to systemic diseases remains unclear despite the systemic nature of the condition. Genetics and environmental factors have recently been implicated in its development.
What is still missing is a clear understanding of the systemic disease links, a reliable early diagnostic test that does not require biopsy, and large-scale prospective studies to clarify environmental triggers and genetic penetrance across populations. No treatment trials are reported in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acta Ophthalmologica · 1988 · 73 citations
PREVALENCE OF EXFOLIATION SYNDROME IN FINLAND
AbstractThree separate investigations are reported, covering a total of 795 patients from different parts of Finland, two of them consisting of inmates of old people's homes in two towns (N = 205 and 262) and one a randomly selected population from a rural commune (N = 328). They show the mean prevalence of exfoliation syndrome (PS) to be 14.2% in age group 60 less than or equal to 69 years, 21.9% in age group 70-79 and 34.7% in age group greater than or equal to 80. The prevalence increases statistically significantly with age. The mean prevalence of PS in all three groups was 22.4%. No isolate-like accumulation of PS could be demonstrated. The figures seem representative of the hole country.
Early diagnosis of exfoliation syndrome in the offspring of affected patients
AbstractPURPOSE: To determine whether conjunctival biopsy in the offspring of patients with exfoliation syndrome (XFS) can provide early diagnosis of the disease. METHODS: Patients with XFS with or without glaucoma were invited to ask their sons and daughters over the age of 40 years to participate in the study. After a complete eye examination, those without clinically evident XFS underwent conjunctival biopsy. The specimens were examined by transmission electron microscopy. RESULTS: A total of 17 sons and daughters (seven men, 10 women) of 17 patients were enrolled. Their mean age was 50.3 +/- 8 years. Twelve specimens were negative and five presented precursor material evidence of typical exfoliation material. CONCLUSION: Evidence of early deposition of exfoliation material can be found in the conjunctiva of the middle-aged offspring of patients with XFS, substantiating the existence of a hereditary predisposition to this disease.
International Journal of Ophthalmology & Eye Science · 2015 · 0 citations · open access
Exfoliation Syndrome
AbstractThe age-related systemic condition called pseudoexfoliation syndrome or exfoliation syndrome underlies a myriad of ocular findings and abnormalities. The best known relationship is to glaucoma; however, all parts of the eye may be affected. The link to systemic diseases is not as clear despite the systemic nature of the condition. Recently, genetics and environmental factors have been found to play a role in its development.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
